<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">World J Surg Oncol</journal-id>
      <journal-id journal-id-type="iso-abbrev">World J Surg Oncol</journal-id>
      <journal-title-group>
        <journal-title>World Journal of Surgical Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1477-7819</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25029913</article-id>
      <article-id pub-id-type="pmc">4105234</article-id>
      <article-id pub-id-type="publisher-id">1477-7819-12-220</article-id>
      <article-id pub-id-type="doi">10.1186/1477-7819-12-220</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Necrolytic migratory erythema as the first manifestation of pancreatic neuroendocrine tumor</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Wu</surname>
            <given-names>Sheng-li</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>shengliyili@hotmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Bai</surname>
            <given-names>Ji-gang</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>bjgxa@126.com</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Xu</surname>
            <given-names>Jun</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>xujun@163.com</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Ma</surname>
            <given-names>Qing-yong</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>qyma56@mail.xjtu.edu.cn</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A5">
          <name>
            <surname>Wu</surname>
            <given-names>Zheng</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>victorywu@163.com</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi&#x2019;an Jiaotong University School of Medicine, No. 277, Yanta West Road, 710061 Xi&#x2019;an, Shaanxi, P.R. China</aff>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>17</day>
        <month>7</month>
        <year>2014</year>
      </pub-date>
      <volume>12</volume>
      <fpage>220</fpage>
      <lpage>220</lpage>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>4</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>4</day>
          <month>7</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 Wu et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder>Wu et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.wjso.com/content/12/1/220"/>
      <abstract>
        <p>Necrolytic migratory erythma (NME) is an obligatory paraneoplastic syndrome. Here we describe a woman admitted to the dermatology ward with NME which was later found to be associated with glucagonoma, a slow-growing, rare pancreatic neuroendocrine tumor. Even more rarely, the tumor was located in the pancreas head, while most of such lesions are located in the distal pancreas. The diagnosis of this rare tumor requires an elevated serum glucagon level and imaging confirming a pancreatic tumor. After surgical removal of the tumor, the patient&#x2019;s cutaneous and systemic features resolved. It is therefore imperative that clinicians recognize NME early in order to make an accurate diagnosis and to provide treatment for this rare tumor.</p>
      </abstract>
      <kwd-group>
        <kwd>Necrolytic migratory erythema</kwd>
        <kwd>Glucagonoma</kwd>
        <kwd>Pancreatic neuroendocrine tumors</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Necrolytic migratory erythema (NME) is a rare skin disorder which was first described by Becker et al. in 1942
[<xref ref-type="bibr" rid="B1">1</xref>]. Erythematous scaly lesions with centrifugal growth characterize the clinical appearance of the disease. Perineum, distal extremities, lower abdomen, and face are the most commonly affected sites
[<xref ref-type="bibr" rid="B2">2</xref>]. NME is an obligatory paraneoplastic syndrome. Most of NME cases are associated with pancreatic neuroendocrine tumors (PNETs). PNETs are rare neoplasms representing &lt;5% of all pancreatic malignancies with an estimated incidence of 1 to 1.5 cases/100,000
[<xref ref-type="bibr" rid="B3">3</xref>] and are classified by the hormonal products that they produce. Glucagonomas, considered among the rarest of PNETs, produce a well defined clinical syndrome characterized by NME, diabetes mellitus, glossitis, anemia, and weight loss
[<xref ref-type="bibr" rid="B4">4</xref>]. In this paper, we describe a woman admitted to the dermatology ward with NME, which was later found to be associated with glucagonoma located at the head of the pancreas. We will describe NME, the glucagonoma syndrome and how to recognize and treat this rare tumor.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 44-year-old woman presented with a 3-month history of pruritic rash of the extremities and oral cavity. The rash progressed to involve the groin, abdomen, axillae, and gluteal region. She was found to have well demarcated, erythematous plaques in these regions. Tiny fragile vesicles were observed at the margins of several plaques (Figure&#xA0;
<xref ref-type="fig" rid="F1">1</xref>). At this time, the patient was admitted to the dermatology ward for further evaluation. The patient underwent allergen patch testing, which was negative, and was treated with topical steroids without clinical improvement. Skin biopsy revealed psoriasiform acanthosis and abrupt necrosis of the upper layers of stratum; whereas the lower half of epidermis appears viable, the detached necrolytic portion appears pale with pyknotic nuclei. Perivascular lymphocytic infiltration and scattered extravasated red blood cells were present in the upper dermis.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Close-up view of well demarcated erythematous plaques, with fragile vesicles on gluteal area.</p>
        </caption>
        <graphic xlink:href="1477-7819-12-220-1"/>
      </fig>
      <p>Based on these findings, NME was considered. A glucagon level was obtained and a contrast-enhanced CT scan was conducted. Her level of serum glucagon was elevated at 720&#xA0;ng/L (normal values 40 to 130&#xA0;ng/L) (Table&#xA0;
<xref ref-type="table" rid="T1">1</xref>) and the scan revealed a 3-cm enhancing pancreatic head mass (Figure&#xA0;
<xref ref-type="fig" rid="F2">2</xref>). Thus, a referral to the hepatobiliary department was made.</p>
      <table-wrap position="float" id="T1">
        <label>Table 1</label>
        <caption>
          <p>Laboratory values on the day of hospital admission and hospital day 14 (post-operative day 7)</p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th align="left">
                <bold>Serum laboratory studies</bold>
              </th>
              <th align="left">
                <bold>Admission values</bold>
              </th>
              <th align="left">
                <bold>Post-operative values</bold>
              </th>
              <th align="left">
                <bold>Normal values</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="bottom">Glucose (mg/dL)<hr/></td>
              <td align="left" valign="bottom">132<hr/></td>
              <td align="left" valign="bottom">85<hr/></td>
              <td align="left" valign="bottom">60&#x2013;99<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Glucagon (ng/L)<hr/></td>
              <td align="left" valign="bottom">720<hr/></td>
              <td align="left" valign="bottom">233<hr/></td>
              <td align="left" valign="bottom">40&#x2013;130<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Chromogranin A (ng/mL)<hr/></td>
              <td align="left" valign="bottom">243<hr/></td>
              <td align="left" valign="bottom">87<hr/></td>
              <td align="left" valign="bottom">&lt;96<hr/></td>
            </tr>
            <tr>
              <td align="left">Glycosylated hemoglobin (%)</td>
              <td align="left">6.3</td>
              <td align="left">4.2</td>
              <td align="left">&lt;5.7</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>Contrast-enhanced computed tomography scan of the abdomen.</bold> A 3-cm nodular mass in the head of the pancreas was seen. There was no evidence of metastases.</p>
        </caption>
        <graphic xlink:href="1477-7819-12-220-2"/>
      </fig>
      <p>On admission, she had stable vital signs. Admission laboratory measurements demonstrated hyperglycemia (132&#xA0;mg/dL, normal values 60 to 99&#xA0;mg/dL) and anemia (hemoglobin 11.4, normal values 12 to 16&#xA0;g/dL). Serum levels of chromogranin A, a tumor marker for neuroendocrine tumors, were elevated (243&#xA0;ng/mL, normal value &lt;96&#xA0;ng/mL), as were levels of glycosylated hemoglobin (6.3%, normal value &lt;5.7%) and the patient was diagnosed with diabetes mellitus.</p>
      <p>On hospital day 7, she underwent pancreaticoduodenectomy. Pathology confirmed a pancreatic neuroendocrine carcinoma with evidence of vascular and perineural invasion, consistent with a diagnosis of a glucagonoma. In the days following her operation, the patient was admitted to the ICU, where she faced pancreatic fistula that resolved with non-operative care. Her glucagon and glucose blood levels dropped dramatically post-operatively (Table&#xA0;
<xref ref-type="table" rid="T1">1</xref>). One week after the surgery, the patient's cutaneous lesions almost disappeared. Currently, more than 1&#xA0;year post-operatively, there was no sign of cutaneous or systemic disease.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>Glucagonoma is a slow growing PNET, which is often heralded by paraneoplastic phenomena. The key features of the glucagonoma syndrome, a rare disorder with an estimated incidence of 1 in 20 million
[<xref ref-type="bibr" rid="B5">5</xref>], are NME and diabetes mellitus
[<xref ref-type="bibr" rid="B6">6</xref>]. Other common manifestations include weight loss, stomatitis, steatorrhea, diarrhea, thromboembolic tendency, anemia, and neuropsychiatric features
[<xref ref-type="bibr" rid="B7">7</xref>]. Males and females are equally affected, with an age peak presentation in the fifth decade of life
[<xref ref-type="bibr" rid="B8">8</xref>]. The diagnosis of a glucagonoma requires an elevated serum glucagon level and imaging confirming a pancreatic tumor. Unfortunately, delays in diagnosis are common for this slow growing tumor. It may proceed at least 1&#xA0;year before a correct diagnosis is made
[<xref ref-type="bibr" rid="B9">9</xref>]. At least half of patients will have metastatic disease when diagnosed
[<xref ref-type="bibr" rid="B10">10</xref>]. Delays in diagnosis have been attributed to the extreme rarity of the tumor, under-recognition of the dermatologic presentation, the difficulty making the diagnosis of NME on biopsy, and the lack of specificity of the other symptoms
[<xref ref-type="bibr" rid="B11">11</xref>].</p>
      <p>NME is the most specific feature of the syndrome, and is the presenting symptom in approximately 70% of patients
[<xref ref-type="bibr" rid="B9">9</xref>]. The exact cause of NME remains unknown. Although normalization of glucagon level by resection of the tumor usually results in a rapid disappearance of the skin disorder
[<xref ref-type="bibr" rid="B12">12</xref>], elevation of serum glucagon levels alone cannot explain all of the skin findings, since hyperglucagonemia occurring in other situations, such as trauma, burns, diabetic ketoacidosis starvation and cirrhosis, does not lead to a typical rash
[<xref ref-type="bibr" rid="B13">13</xref>]. Hypoaminoacidemia or other nutritional deficiencies, such as essential fatty acids or zinc, might also contribute to the occurrence of NME because of the cutaneous histologic similarities between these deficiency states and this syndrome
[<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. The early recognition and correct diagnosis of NME is important because it can be the only and the first manifestation of the glucagonoma syndrome. However, the correct diagnosis of NME is challenging as the lesions of the NME may be often misinterpreted as contact dermatitis, intertrigo, inverse psoriasis, zinc deficiency, and other nutritional deficiencies
[<xref ref-type="bibr" rid="B7">7</xref>].</p>
      <p>Diabetes mellitus is another common finding. Glucagon has many important effects on glucose metabolism. It stimulates hepatic gluconeogenesis, inhibits glycolysis and glycogen synthesis. Case studies suggest that 80% of patients with glucagonomas will eventually develop the disease
[<xref ref-type="bibr" rid="B12">12</xref>].</p>
      <p>Glucagonomas are typically distal pancreatic tumors, generally large in size due to late detection, often measuring between 4 and 10&#xA0;cm
[<xref ref-type="bibr" rid="B16">16</xref>]. However, the tumor in our patient was located in the head of the pancreas, which is uncommon for this disease. Moreover, the tumor was detected in its early stage due to the prompt and accurate diagnosis.</p>
      <p>Contrast-enhanced CT is recommended to identify the number and location of tumors. Somatostatin receptor scintigraphy may be obtained if there is concern for distant disease
[<xref ref-type="bibr" rid="B17">17</xref>]. The best and the most effective treatment strategy should aim to lower serum glucagon levels. A complete resection of the tumor is the best option because of its weak response to chemotherapy
[<xref ref-type="bibr" rid="B14">14</xref>]. Patients who underwent resection had significantly longer median survival than patients who did not receive surgery, even when diagnosed with later stages of disease
[<xref ref-type="bibr" rid="B18">18</xref>].</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for the publication of this report and any accompanying images.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>CT: computed tomography; NME: necrolytic migratory erythma; PNET: pancreatic neuroendocrine tumor.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>SLW and ZW conceived and designed the study. JGB and JX collected the clinical data. SLW and QYM wrote the manuscript. All authors approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Becker</surname>
            <given-names>SW</given-names>
          </name>
          <name>
            <surname>Brennan</surname>
            <given-names>BB</given-names>
          </name>
          <article-title>Benign and malignant cutaneous tumors in the elderly</article-title>
          <source>Arch Dermatol</source>
          <year>1961</year>
          <volume>83</volume>
          <fpage>262</fpage>
          <lpage>271</lpage>
          <pub-id pub-id-type="pmid">14448530</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Afsharfard</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Atqiaee</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Lotfollahzadeh</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Alborzi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Derakhshanfar</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Necrolytic migratory erythema as the first manifestation of glucagonoma</article-title>
          <source>Case Rep Surg</source>
          <year>2012</year>
          <volume>2012</volume>
          <fpage>974210</fpage>
          <pub-id pub-id-type="pmid">22970401</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Batcher</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Madaj</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Gianoukakis</surname>
            <given-names>AG</given-names>
          </name>
          <article-title>Pancreatic neuroendocrine tumors</article-title>
          <source>Endocr Res</source>
          <year>2011</year>
          <volume>36</volume>
          <fpage>35</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="pmid">21226566</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Edney</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Hofmann</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Thompson</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Kessinger</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Glucagonoma syndrome is an underdiagnosed clinical entity</article-title>
          <source>Am J Surg</source>
          <year>1990</year>
          <volume>160</volume>
          <fpage>625</fpage>
          <lpage>628</lpage>
          <pub-id pub-id-type="pmid">2252125</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Wermers</surname>
            <given-names>RA</given-names>
          </name>
          <name>
            <surname>Fatourechi</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Wynne</surname>
            <given-names>AG</given-names>
          </name>
          <name>
            <surname>Kvols</surname>
            <given-names>LK</given-names>
          </name>
          <name>
            <surname>Lloyd</surname>
            <given-names>RV</given-names>
          </name>
          <article-title>The glucagonoma syndrome. Clinical and pathologic features in 21 patients</article-title>
          <source>Medicine</source>
          <year>1996</year>
          <volume>75</volume>
          <fpage>53</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="pmid">8606627</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Johnson</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Smoller</surname>
            <given-names>RB</given-names>
          </name>
          <name>
            <surname>Lamps</surname>
            <given-names>LW</given-names>
          </name>
          <name>
            <surname>Horn</surname>
            <given-names>TD</given-names>
          </name>
          <article-title>Necrolytic migratory erythema as the only presenting sign of a glucagonoma</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2003</year>
          <volume>49</volume>
          <fpage>325</fpage>
          <lpage>328</lpage>
          <pub-id pub-id-type="pmid">12894090</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Lobo</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Carvalho</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Amaral</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Machado</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Carvalho</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Glucagonoma syndrome and necrolytic migratory erythema</article-title>
          <source>Int J Dermatol</source>
          <year>2010</year>
          <volume>49</volume>
          <fpage>24</fpage>
          <lpage>29</lpage>
          <pub-id pub-id-type="pmid">20465606</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Doherty</surname>
            <given-names>GM</given-names>
          </name>
          <article-title>Rare endocrine tumours of the GI tract</article-title>
          <source>Best Pract Res Clin Gastroenterol</source>
          <year>2005</year>
          <volume>19</volume>
          <fpage>807</fpage>
          <lpage>818</lpage>
          <pub-id pub-id-type="pmid">16253902</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Eldor</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Glaser</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Fraenkel</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Doviner</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Salmon</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Gross</surname>
            <given-names>DJ</given-names>
          </name>
          <article-title>Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour</article-title>
          <source>Clin Endocrinol</source>
          <year>2011</year>
          <volume>74</volume>
          <fpage>593</fpage>
          <lpage>598</lpage>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Echenique-Elizondo</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tuneu Valls</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Elorza Or&#xFA;e</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Martinez De Lizarduy</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Ib&#xE1;&#xF1;ez Aguirre</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Glucagonoma and pseudoglucagonoma syndrome</article-title>
          <source>JOP</source>
          <year>2004</year>
          <volume>5</volume>
          <fpage>179</fpage>
          <lpage>185</lpage>
          <pub-id pub-id-type="pmid">15254346</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Halvorson</surname>
            <given-names>SA</given-names>
          </name>
          <name>
            <surname>Gilbert</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Hopkins</surname>
            <given-names>RS</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Lopez</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Chu</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Martin</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sheppard</surname>
            <given-names>B</given-names>
          </name>
          <article-title>Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome</article-title>
          <source>J Gen Intern Med</source>
          <year>2013</year>
          <volume>28</volume>
          <fpage>1525</fpage>
          <lpage>1529</lpage>
          <pub-id pub-id-type="pmid">23681843</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Van Beek</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>De Haas</surname>
            <given-names>ER</given-names>
          </name>
          <name>
            <surname>Van Vloten</surname>
            <given-names>WA</given-names>
          </name>
          <name>
            <surname>Lips</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Roijers</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Canninga-van Dijk</surname>
            <given-names>MR</given-names>
          </name>
          <article-title>The glucagonoma syndrome and necrolytic migratory erythema: a clinical review</article-title>
          <source>Eur J Endocrinol</source>
          <year>2004</year>
          <volume>151</volume>
          <fpage>531</fpage>
          <lpage>537</lpage>
          <pub-id pub-id-type="pmid">15538929</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Adam</surname>
            <given-names>DN</given-names>
          </name>
          <name>
            <surname>Cohen</surname>
            <given-names>PD</given-names>
          </name>
          <name>
            <surname>Ghazarian</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Necrolytic migratory erythema: case report and clinical review</article-title>
          <source>J Cutan Med Surg</source>
          <year>2003</year>
          <volume>7</volume>
          <fpage>333</fpage>
          <lpage>338</lpage>
          <pub-id pub-id-type="pmid">14738101</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Alexander</surname>
            <given-names>EK</given-names>
          </name>
          <name>
            <surname>Robinson</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Staniec</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dluhy</surname>
            <given-names>RG</given-names>
          </name>
          <article-title>Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome</article-title>
          <source>Clin Endocrinol</source>
          <year>2002</year>
          <volume>57</volume>
          <fpage>827</fpage>
          <lpage>831</lpage>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Chastain</surname>
            <given-names>MA</given-names>
          </name>
          <article-title>The glucagonoma syndrome: a review of its features and discussion of new perspectives</article-title>
          <source>Am J Med Sci</source>
          <year>2001</year>
          <volume>321</volume>
          <fpage>306</fpage>
          <lpage>320</lpage>
          <pub-id pub-id-type="pmid">11370794</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Akerstr&#xF6;m</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Hellman</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Surgical aspects of neuroendocrine tumours</article-title>
          <source>Eur J Cancer</source>
          <year>2009</year>
          <volume>45</volume>
          <fpage>237</fpage>
          <lpage>250</lpage>
          <pub-id pub-id-type="pmid">19775622</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sundin</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Garske</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Orlefors</surname>
            <given-names>H</given-names>
          </name>
          <article-title>Nuclear imaging of neuroendocrine tumours</article-title>
          <source>Best Pract Res Clin Endocrinol Metab</source>
          <year>2007</year>
          <volume>21</volume>
          <fpage>69</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="pmid">17382266</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Hill</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>McPhee</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>McDade</surname>
            <given-names>TP</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Sullivan</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Whalen</surname>
            <given-names>GF</given-names>
          </name>
          <name>
            <surname>Tseng</surname>
            <given-names>JF</given-names>
          </name>
          <article-title>Pancreatic neuroendocrine tumors: the impact of surgical resection on survival</article-title>
          <source>Cancer</source>
          <year>2009</year>
          <volume>115</volume>
          <fpage>741</fpage>
          <lpage>751</lpage>
          <pub-id pub-id-type="pmid">19130464</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
